Adaptin Bio (APTN) Return on Equity (2023 - 2026)

Adaptin Bio has disclosed Return on Equity across 4 years of filings, most recently posting 0.04% for Q1 2026.

• Quarterly Return on Equity rose 1.0% year-over-year to 0.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (up 1.0% YoY) and the FY2025 annual result came in at 0.02%, up 1.0% from the prior year.
• Return on Equity retreated to 0.04% in Q1 2026, from 0.04% in the prior quarter.
• Across five years, Return on Equity topped out at 0.23% in Q3 2025 and bottomed at 0.04% in Q2 2025.
• The 4-year median for Return on Equity is 0.01% (2024), against an average of 0.03%.
• The widest YoY moves for Return on Equity: up 22 bps in 2025, down 4 bps in 2025.
• Adaptin Bio's Return on Equity stood at 0.0% in 2023, then soared by 483 bps to 0.01% in 2024, then soared by 416 bps to 0.04% in 2025, then retreated by 20 bps to 0.04% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.04%, 0.04%, and 0.23% for Q1 2026, Q4 2025, and Q3 2025 respectively.